MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: A meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 8, 2011, Pages 1899-1903

  Liu, Jun ^a   Zheng, Youyang ^b   Lei, Dapeng ^a   Liu, Dayu ^a   Xu, Fenglei ^a   Jin, Tong ^a   Cao, Xiaolin ^c   Zhao, Xuening ^a   Yu, Xuemin ^a   Pan, Xinliang ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

Author keywords

Head and neck squamous cell carcinomas; MDM2 SNP309T>G; Meta analysis; Polymorphism

Indexed keywords

EID: 84863292883     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Alhopuro P (2005). The MDM2 promoter polymorphism SNP309T->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck. J Med Genetics, 42, 694-8.
2. Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
3. Brennan P, Boffetta P (2004). Mechanistic considerations in the molecular epidemiology of head and neck cancer. IARC Sci Publ, 393-414.
4. Canova C, Hashibe M, Simonato L, et al (2009). Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: The ARCAGE Project. Cancer Res, 69, 2956-65.
5. Chen X, Sturgis EM, Lei D, et al (2010). Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res, 70, 7199-208.
6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 77-88.
7. Economopoulos KP, Sergentanis TN (2010). Differential effects of MDM2 SNP309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat, 120, 211-6.
8. Efeyan A, Serrano M (2007). p53: guardian of the genome and policeman of the oncogenes. Cell Cycle, 6, 1006-10.
9. Fakhry C, Gillison ML (2006). Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol, 24, 2606-11.
10. Fang F, Yu XJ, Yu L, Yao L (2010). MDM2 309 T/G polymorphism is associated with colorectal cancer risk especially in Asians: a meta-analysis. Med Oncol, 28, 981-5.
11. Freedman DA, Levine AJ (1999). Regulation of the p53 protein by the MDM2 oncoprotein-thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res, 59, 1-7.
12. Hamid S, Yang Y-H, Peng KNL, et al (2009). MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. Oral Oncol, 45, 496-500.
13. Haupt Y, Maya R, Kazaz A, Oren M (1997). Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-9.
14. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991). p53 mutations in human cancers. Science, 253, 49-53.
15. Hu Z, Jin G, Wang L, et al (2007). MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev, 16, 2717-23.
16. Huang S, Chen I, Liao C, et al (2009).Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol, 45, 16-22.
17. Jemal A, Murray T, Ward E, et al (2005). Cancer statistics, 2005. CA Cancer J Clin, 55, 10-30.
18. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A (1998). Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci USA, 95, 15608-12.
19. Lescaille G, Descroix V, Azerad J (2011). Papillomavirus and head and neck cancer. Rev Stomatol Chir Maxillofac. ??, ?? (in French).
20. Li G, Zhai X, Zhang Z, et al (2006). MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. Carcinogenesis, 27, 2028-33.
21. Liu GY, Jiang DK, Shen SQ, Yu L (2011). MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: A meta-analysis. Arch Med Res, 42, 149-55.
22. Macaskill P, Walter SD, Irwig L (2001). A comparison of methods to detect publication bias in meta-analysis. Stat Med, 20, 641-54.
23. Mayo LD, Donner DB (2002). The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci, 27, 462-7.
24. Millon R, Muller D, Schultz I, et al (2001). Loss of MDM2 expression in human head and neck squamous cell carcinomas and clinical significance. Oral Oncol, 37, 620-31.
25. Misra C, Majumder M, Bajaj S, et al (2009). Polymorphisms atp53, p73, andMDM2loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinogenesis, 48, 790-800.
26. Nakashima M, Kondo S, Shimizu Y, et al (2008). Impact ofMDM2single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Oto-laryngologica, 128, 808-13.
27. Nylander K, Dabelsteen E, Hall PA (2000) The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med, 29, 413-25.
28. Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C (2008). Alcohol and tobacco use, and cancer risk for upper aerodigestive tract and liver. Eur J Cancer Prev, 17, 340-4.
29. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B (1997). A model for p53-induced apoptosis. Nature, 389, 300-5.
30. Poyurovsky MV, Prives C (2006). Unleashing the power of p53: lessons from mice and men. Genes Dev, 20, 125-31.
31. Rasidakis A, Orphanidou D, Kalomenidis J, et al (1998). Expression of mdm-2 protein in neoplastic, preneoplastic, and normal bronchial mucosa specimens: comparative study with p53 expression. Hybridoma, 17, 339-45.
32. Stockwell HG, Lyman GH (1986). Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. Head Neck Surg, 9, 104-10.
33. Tu H, Chen H, Kao S, et al (2008). MDM2 SNP 309 and p53p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation. Radiother Oncol, 87, 243-52.
34. Wang B, Wang D, Huang G, et al (2010). XRCC1 polymorphisms and risk of colorectal cancer: a meta-analysis. Int J Colorectal Dis, 25, 313-21.
35. Wilkening S, Bermejo JL, Hemminki K (2007). MDM2 SNP309 and cancer risk: a combined analysis. Carcinogenesis, 28, 2262-7.
36. Zintzaras E, Ioannidis JP (2005). Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol, 28, 123-37.
37. Zintzaras E, Lau J (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J Clin Epidemiol, 61, 634-45.